Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of TAK-071 in Healthy and MCI/Mild AD Subjects
NCT02769065Phase 1Terminated
- Sponsor
- Takeda
- Start
- May 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tak-071 in Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD) (5 arms), sponsored by Takeda. Primary endpoints: Percentage of Participants Who Experienced at Least One Treatment-Emergent Adverse Event, Percentage of Participants Who Meet the Markedly Abnormal Criteria for Clinical Laboratory Tests and 6 more. Started May 2016; status: terminated.
02
Drugs
tak-071
03
Conditions
Mild Cognitive Impairment (MCI)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02769065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02769065.